Impact of Prior Oral Anticoagulant Use and Outcomes on Patients from Secondary Analysis in the AUGUSTUS Trial

Overview

Journal Open Heart

Publisher BMJ Publishing Group

Specialty Cardiology & Vascular Diseases

Date 2022 Feb 17

PMID 35172988

Authors

Robert C Welsh

Payam Dehghani

Renato Lopes

Daniel M Wojdyla

Ronald Aronson

Christopher B Granger

Stephan Windecker

Amit N Vora

Dragos Vinereanu

Sigrun Halvorsen

Alexander Parkhomenko

Roxana Mehran

John H Alexander

Shaun Goodman

Affiliations

Soon will be listed here.

Abstract

Objective: Managing antithrombotic therapy in patients with atrial fibrillation (AF) and an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI) is challenging and can be affected by prior oral anticoagulant (OAC) treatment. We examined the relationship between prior OAC use and outcomes in the AUGUSTUS trial.

Methods: This prespecified secondary analysis is from AUGUSTUS, an open-label, 2-by-2 factorial, RCT to evaluate the safety of apixaban versus vitamin K antagonist (VKA) and aspirin versus placebo in patients with AF and ACS and/or PCI. The primary endpoint, major or clinically relevant non-major bleeding and clinical outcomes were compared in patients receiving (n=2262) or not receiving (n=2352) an OAC prior to enrolment.

Results: Patients with prior OAC use had more comorbidities, higher CHADS-VASC and HAS-BLED scores, and were more likely enrolled following elective PCI. There was no difference in major or clinically relevant non-major bleeding with or without prior OAC (30 days: 5.1% vs 5.9% (adjusted HR (aHR) 0.82, 95% CI 0.63 to 1.06); 180 days: 13.5% vs 13.5% (aHR 0.98, 95% CI 0.83 to 1.16)). Patients with prior OAC use had a lower risk of death or ischaemic events (30 days: 1.7% vs 2.8% (aHR 0.61, 95% CI 0.41 to 0.92); 180 days: 5.4% vs 7.6% (aHR 0.70, 95% CI 0.55 to 0.88)). No interactions between randomised treatment (apixaban vs VKA, aspirin vs placebo) and prior OAC status were observed for outcomes, apart from apixaban (vs VKA) being associated with a lower risk of myocardial infarction with prior OAC use (180 days: 2.0% vs 3.7% (aHR 0.56, 95% CI 0.33 to 0.91().

Conclusions: In AUGUSTUS, prior OAC use was associated with fewer ischaemic events but not more bleeding. In patients with AF and ACS and/or undergoing PCI, clinicians can be assured that the trial results can be applied to patients regardless of their prior OAC status.

Trial Registration Number: NCT02415400.

References

Depta J, Bhatt D . Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes. Thromb Haemost. 2010; 104(4):657-63. DOI: 10.1160/TH10-05-0332. View

Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P . Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based.... Eur Heart J. 2019; 40(46):3757-3767. DOI: 10.1093/eurheartj/ehz732. View

Gibson C, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P . Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375(25):2423-2434. DOI: 10.1056/NEJMoa1611594. View

Maura G, Blotiere P, Bouillon K, Billionnet C, Ricordeau P, Alla F . Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort.... Circulation. 2015; 132(13):1252-60. PMC: 4885525. DOI: 10.1161/CIRCULATIONAHA.115.015710. View

Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G . Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019; 394(10206):1335-1343. DOI: 10.1016/S0140-6736(19)31872-0. View

Bouillon K, Bertrand M, Maura G, Blotiere P, Ricordeau P, Zureik M . Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol. 2015; 2(4):e150-9. DOI: 10.1016/S2352-3026(15)00027-7. View

Mahaffey K, Wojdyla D, Hankey G, White H, Nessel C, Piccini J . Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med. 2013; 158(12):861-8. DOI: 10.7326/0003-4819-158-12-201306180-00003. View

Dewilde W, Janssen P, Kelder J, Verheugt F, de Smet B, Adriaenssens T . Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention. 2014; 11(4):381-90. DOI: 10.4244/EIJY14M06_07. View

Lopes R, Heizer G, Aronson R, Vora A, Massaro T, Mehran R . Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019; 380(16):1509-1524. DOI: 10.1056/NEJMoa1817083. View

10.

Granger C, Lopes R, Hanna M, Ansell J, Hylek E, Alexander J . Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2014; 169(1):25-30. DOI: 10.1016/j.ahj.2014.09.006. View

11.

Ruff C, Bhatt D, Steg P, Gersh B, Alberts M, Hoffman E . Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol. 2013; 170(3):413-8. DOI: 10.1016/j.ijcard.2013.11.030. View

12.

Lopes R, Vora A, Liaw D, Granger C, Darius H, Goodman S . An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary.... Am Heart J. 2018; 200:17-23. DOI: 10.1016/j.ahj.2018.03.001. View

13.

Mahaffey K, Hellkamp A, Patel M, Hannan K, Schwabe K, Nessel C . End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circ Cardiovasc Qual Outcomes. 2013; 6(4):470-8. DOI: 10.1161/CIRCOUTCOMES.113.000132. View

14.

Ruff C, Giugliano R, Braunwald E, Mercuri M, Curt V, Betcher J . Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2014; 64(6):576-84. DOI: 10.1016/j.jacc.2014.05.028. View

15.

Cannon C, Bhatt D, Oldgren J, Lip G, Ellis S, Kimura T . Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017; 377(16):1513-1524. DOI: 10.1056/NEJMoa1708454. View

16.

Lahtela H, Rubboli A, Schlitt A, Karjalainen P, Niemela M, Vikman S . Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry. Circ J. 2012; 76(6):1363-8. DOI: 10.1253/circj.cj-11-1206. View

17.

Goto S, Bhatt D, Rother J, Alberts M, Hill M, Ikeda Y . Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008; 156(5):855-63, 863.e2. DOI: 10.1016/j.ahj.2008.06.029. View